We recommend you use Internet Explorer 10 or above, Firefox or Google Chrome to visit the site.

Opening Lecture (Nobel Lecture)

Speaker:  Tasuku Honjo (Kyoto University) 


Date: Sunday, 27th September 2020
Time: 18:00-19:00
Venue: 201 Meeting Room,  
            2F, Taipei International Convention Center (TICC) 
Language: English


------------------------------------------------------------------------------------------------------------------------------------

Opening Ceremony

Date: Sunday, 27th September 2020
Time: 17:30-18:00
Venue: 201 Meeting Room,  
            2F, Taipei International Convention Center (TICC) 


Dr. Honjo entered the Kyoto University medical school in 1960, and completed a graduate course at the university in 1971. He has been awarded a fellowship to study at the Carnegie Institution for Science and the U.S. National Institutes of Health, where he carried out research on the immune response. Following study in the United States, he became a professor at Osaka University in 1979 when he was 37. He moved to the faculty of Kyoto University in 1984, and achieved a number of breakthroughs including the discovery of PD-1. He became professor emeritus at the university in 2005 and currently serves as Deputy Director-General and Distinguished Professor of  Kyoto University Institute for Advanced Study.  
 (https://mainichi.jp/english/articles/20181001/p2a/00m/0na/029000c)

Dr. Honjo is well known for his discovery of activation-induced cytidine deaminase (AID) that is essential for class switch recombination and somatic hypermutation. He has established the basic conceptual framework of class switch recombination starting from discovery of DNA deletion. He also identified a series of key molecules involved in immune regulation, including IL-4, IL-5, SDF-1, and IL-2R αchain. 
(https://kuias.kyoto-u.ac.jp/e/profile/honjo/)

Dr. Honjo won the 2018 Nobel Prize in physiology and medicine for his discovery of PD-1, a negative coreceptor at the effector phase of immune response. PD-1 is a protein that regulates immune system function, its modulation contributes to treatments of tumor, viral infection and autoimmunity. His findings opened the way for the development of anti-PD-1 cancer immunotherapies, including nivolumab and pembrolizumab, which were approved for the treatment of melanoma and certain other cancers. In addition to the Nobel Prize, he also received a number of prestigious prizes, including Imperial Prize, Japan Academy Prize, Robert Koch Prize, Order of Culture, the Tang Prize, the Kyoto Prize. 
(https://www.britannica.com/biography/Tasuku-Honjo, http://www.wcp2018.org/program/bio/Tasuku_Honjo.html)